Last reviewed · How we verify
Centers for Disease Control and Prevention, China — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
1 Phase 2
3 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Sabin IPV | Sabin IPV | marketed | inactivated viral vaccine | poliovirus serotypes 1, 2, and 3 | Immunology / Infectious Disease |
Therapeutic area mix
- Immunology / Infectious Disease · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Beijing Chaoyang District Centre for Disease Control and Prevention · 1 shared drug class
- Centers for Disease Control and Prevention · 1 shared drug class
- Federal University of Espirito Santo · 1 shared drug class
- International Vaccine Institute · 1 shared drug class
- MacroGenics · 1 shared drug class
- Sanofi Pasteur, a Sanofi Company · 1 shared drug class
- Shandong Province Centers for Disease Control and Prevention · 1 shared drug class
- Sinovac Biotech Co., Ltd · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Centers for Disease Control and Prevention, China:
- Centers for Disease Control and Prevention, China pipeline updates — RSS
- Centers for Disease Control and Prevention, China pipeline updates — Atom
- Centers for Disease Control and Prevention, China pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Centers for Disease Control and Prevention, China — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/centers-for-disease-control-and-prevention-china. Accessed 2026-05-17.